CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in CNS Pharmaceuticals, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +3 vs. Q1 2022
- Shares held
- 1.23M
- −499.6K (−28.8%) vs. Q1 2022
- Total value
- $343.5K
- −$245.5K (−41.7%) vs. Q1 2022
- New holders
- 7
- 4 more added
- Sold out
- 4
- 2 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 427,703 | $120.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 203,548 | $57.0K | 0.00% | −31,344−13.3% | Reduced |
| Virtu Financial LLC | 178,184 | $50.0K | 0.00% | +66,435+59.5% | Added |
| Geode Capital Management, LLC | 129,016 | $36.0K | 0.00% | 00.0% | Unchanged |
| FSM Wealth Advisors, LLC | 40,000 | $10.0K | 0.01% | +40,000 | New |
| Northern Trust Corp | 32,094 | $9.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 29,007 | $8.00K | 0.00% | +582+2.0% | Added |
| Cambridge Investment Research Advisors, Inc. | 25,250 | $7.00K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 20,721 | $6.00K | 0.00% | −34,510−62.5% | Reduced |
| State Street Corp | 19,645 | $6.00K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 20,000 | $5.00K | 0.00% | 00.0% | Unchanged |
| United Capital Financial Advisers, LLC | 18,944 | $5.00K | 0.00% | +18,944 | New |
| StoneX Group Inc. | 15,921 | $4.46K | 0.00% | +15,921 | New |
| HighTower Advisors, LLC | 16,000 | $4.00K | 0.00% | +2,500+18.5% | Added |
| Citigroup Inc | 13,400 | $4.00K | 0.00% | +13,400 | New |
| Wells Fargo & Company | 12,196 | $3.00K | 0.00% | +33+0.3% | Added |
| Alpha Cubed Investments, LLC | 10,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 10,384 | $3.00K | 0.00% | +10,384 | New |
| Prime Capital Investment Advisors, LLC | 10,727 | $3.00K | 0.00% | +10,727 | New |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $0 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Urban Wealth Management, LLC | 100 | $0 | 0.00% | +100 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −506,532−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −41,087−100.0% | Sold out |
| Beacon Financial Advisory LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −25,143−100.0% | Sold out |